Natural biology. Groundbreaking approach.
Atara's mission is to unleash the extraordinary power of the body's immune system. By harnessing the compelling biological features of T cells—the immune system's most effective weapon—to target Epstein-Barr virus (EBV), we seek to deliver cell-based innovation in the form of next-generation allogeneic T-cell immunotherapies that aim to change patients' lives worldwide.
Our unique EBV T-cell platform sets us apart.
Our EBV T-cell platform uses allogeneic (donor-derived) T cells, next-generation CAR T technologies, and world-class manufacturing capabilities aimed at harnessing the power of the immune system to target and destroy disease-causing cells. Our platform is unique—and it's what makes Atara well-positioned to deliver on our goal of bringing off-the-shelf immunotherapies to patients in need.Learn More About Our Technology
Board of Directors
We innovate with strategic partners.
As a pioneer of allogeneic T-cell immunotherapy, we're furthering our impact by collaborating with the world's leading academic institutions and companies to develop next-generation technologies.
Memorial Sloan Kettering Cancer Center
In 2015, Atara entered into a license agreement with the Memorial Sloan Kettering Cancer Center for development, manufacturing, and more.
In 2015, we obtained an exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna.
Moffitt Cancer Center
In 2018, we entered into an agreement and collaboration with Moffitt Cancer Center to develop T-cell immunotherapies by Dr. Marco Davila.
Sustainable, ethical business practices.
We support environmental, social, and governance initiatives. Learn how we align our work with our mission, culture, and core values every day.